Advanced Endometrial Cancer (DBCOND0050728)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Carboplatin	A alkylating agent used to treat advanced ovarian cancer.	DNAtarget High affinity copper uptake protein 1transporter Protein SLC31A2transporter Xanthine dehydrogenase/oxidaseenzyme Myeloperoxidaseenzyme Glutathione S-transferase theta-1enzyme Metallothionein-1Aenzyme Metallothionein-2enzyme Superoxide dismutase [Cu-Zn]enzyme Glutathione S-transferase Penzyme Glutathione S-transferase Mu 1enzyme NAD(P)H dehydrogenase [quinone] 1enzyme Copper-transporting ATPase 1transporter Copper-transporting ATPase 2transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-binding cassette sub-family C member 2transporter
Doxorubicin	A medication used to treat various cancers, including AIDS-associated Kaposi's Sarcoma and metastatic cancers.	DNA topoisomerase 2-alphatarget DNAtarget Cytochrome P450 3A4enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2B6enzyme ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 3transporter ATP-binding cassette sub-family C member 6transporter Multidrug resistance-associated protein 1transporter ATP-binding cassette sub-family C member 10transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Bile salt export pumptransporter Solute carrier family 22 member 16transporter Mitochondrial potassium channel ATP-binding subunittransporter Cytochrome P450 1B1enzyme Carbonyl reductase [NADPH] 1enzyme Carbonyl reductase [NADPH] 3enzyme Aldo-keto reductase family 1 member A1enzyme Aldo-keto reductase family 1 member C3enzyme NAD(P)H dehydrogenase [quinone] 1enzyme Xanthine dehydrogenase/oxidaseenzyme Nitric oxide synthase 3enzyme Nitric oxide synthase, inducibleenzyme Nitric oxide synthase 1enzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialenzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrialenzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrialenzyme NADPH--cytochrome P450 reductaseenzyme RalA-binding protein 1transporter ATP-binding cassette sub-family C member 2transporter Albumincarrier Nucleolar and coiled-body phosphoprotein 1target DNA topoisomerase 1target DNA topoisomerase 2-betatarget Aldo-keto reductase family 1 member B1enzyme Aldo-keto reductase family 1 member B10enzyme Aldo-keto reductase family 1 member C4enzyme Telomerase reverse transcriptasetarget
Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05077215	Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer	Lenvatinib Pembrolizumab	treatment	3	not_yet_recruiting
NCT05106127	Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem	Lenvatinib Pembrolizumab	treatment	2	not_yet_recruiting
NCT06584032	Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer	Doxorubicin Fruquintinib Paclitaxel Sintilimab	treatment	3	not_yet_recruiting
NCT01289041	BKM120 as Second-line Therapy for Advanced Endometrial Cancer	Buparlisib	treatment	2	completed
NCT06046274	GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer	Acasunlimab Pembrolizumab	treatment	2	withdrawn
NCT04574284	A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer	APL-502 Anlotinib	treatment	2	unknown_status
NCT05481645	Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.	APL-502 Anlotinib Carboplatin Docetaxel Doxorubicin Gemcitabine Paclitaxel	treatment	2	recruiting
NCT05112991	Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer	Envafolimab Lenvatinib	treatment	2	recruiting